Levomethadyl Acetate

Summary

Levomethadyl Acetate (CHEMBL1514) is an approved small-molecule opioid analgesic (ATC N07BC03); indicated across 2 conditions including drug dependence and opiate dependence.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N07BC03
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 353.5 Da · C23H31NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1514
Name	Levomethadyl Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	15130
ChEBI	CHEBI:6441
ATC	N07BC03
Molecular formula	C23H31NO2
Molecular weight	353.5
InChIKey	XBMIVRRWGCYBTQ-AVRDEDQJSA-N

SMILES: CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C

IUPAC name: [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate

Pharmacological roles (ChEBI): opioid analgesic, μ-opioid receptor antagonist.

Also known as: LAA-M, LAAM, Levacetilmetadol, Levacetylmethadol, Levo-alphacetylmethadol, Levoacetyl methadol, Levomethadyl acetate, Orlaam, L-Acetylmethadol, Levomethadyl, LEVOMETHADYL ACETATE

Parent form; salt/anhydrous children: CHEMBL1200817

Patent coverage: 1,281 distinct patent families (5,016 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.66	IC50	2188	nM	CHEMBL_ACT_1523694

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
drug dependence	4	MONDO:0005303	EFO:0003890
opiate dependence	4	MONDO:0005530	EFO:0005611

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000300	PHASE4	COMPLETED	Feasibility Study of Take-Home LAAM Medication - 3
NCT00000356	PHASE2	COMPLETED	Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5
NCT00158288	PHASE2	COMPLETED	The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
NCT00218127	PHASE2	COMPLETED	Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
NCT01935830	EARLY_PHASE1	COMPLETED	LAAM-HAART PET Imaging

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).